Literature DB >> 30267647

TIGAR inclusion pathology is specific for Lewy body diseases.

Karla L Robles López1, Julie E Simpson1, Lisa C Watson1, Heather Mortiboys1, Guillaume M Hautbergue1, Oliver Bandmann1, J Robin Highley2.   

Abstract

BACKGROUND: We previously reported up-regulation of tigarb (the zebrafish orthologue of human TIGAR, TP53 - Induced Glycolysis and Apoptosis Regulator) in a zebrafish pink1-/- model of Parkinson's disease (PD). Genetic inactivation of tigarb led to the rescue of dopaminergic neurons and mitochondrial function in pink-/- zebrafish. The aim of this study was to determine the relevance of TIGAR for human PD, investigate its disease specificity and identify relevant upstream and downstream mechanisms.
MATERIALS AND METHODS: TIGAR Immunohistochemistry, using a range of antibodies, was undertaken for detailed assessment of TIGAR in formalin-fixed, paraffin-embedded tissue from post mortem brains of PD patients and other neurodegenerative disorders (n = 10 controls, 10 PD cases, 10 dementia with Lewy bodies, 5 motor neurone disease (MND), 3 multiple system atrophy (MSA)) and complemented by immunohistochemistry for p53, hexokinase I (HK-I) and hexokinase II (HK-II; n = 4 control, 4 PD, and 4 dementia with Lewy bodies).
RESULTS: TIGAR was detected in Lewy bodies and Lewy neurites in the substantia nigra of sporadic PD and Dementia with Lewy bodies (DLB) patients. Staining of adjacent sections and double staining confirmed the presence of TIGAR alongside alpha-synuclein in these LB and neurites. In contrast, TIGAR-positive aggregates were not seen in cortical Lewy bodies. TIGAR protein was also absent in both TDP-43-positive inclusions in MND and glial cytoplasmic inclusions in MSA. Subsequent investigation of the TIGAR-upstream regulator p53 and the downstream targets HK-I and HK-II in PD brains suggested a possible mild increase in HK-I.
CONCLUSIONS: TIGAR protein, is present in SN Lewy bodies of both sporadic PD and DLB. The absence of TIGAR protein in the pathological inclusions of MND or MSA suggests disease specificity and further raises the possibility that TIGAR may be involved in PD pathogenesis.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Dementia with Lewy bodies; Lewy body; Parkinson’s disease; Substantia nigra; TIGAR

Mesh:

Substances:

Year:  2018        PMID: 30267647     DOI: 10.1016/j.brainres.2018.09.032

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 2.  Structure, regulation, and biological functions of TIGAR and its role in diseases.

Authors:  Jie Tang; Lei Chen; Zheng-Hong Qin; Rui Sheng
Journal:  Acta Pharmacol Sin       Date:  2021-01-28       Impact factor: 7.169

Review 3.  Peripheral Glycolysis in Neurodegenerative Diseases.

Authors:  Simon M Bell; Toby Burgess; James Lee; Daniel J Blackburn; Scott P Allen; Heather Mortiboys
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

4.  Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.

Authors:  Szu-Ju Chen; Chieh-Chang Chen; Hsin-Yu Liao; Ya-Ting Lin; Yu-Wei Wu; Jyh-Ming Liou; Ming-Shiang Wu; Ching-Hua Kuo; Chin-Hsien Lin
Journal:  Neurology       Date:  2022-01-07       Impact factor: 11.800

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.